Equities Analysts Offer Predictions for Gilead Sciences, Inc.’s Q2 2024 Earnings (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Zacks Research reduced their Q2 2024 EPS estimates for Gilead Sciences in a research note issued on Tuesday, April 23rd. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will earn $1.40 per share for the quarter, down from their prior forecast of $1.54. The consensus estimate for Gilead Sciences’ current full-year earnings is $6.28 per share. Zacks Research also issued estimates for Gilead Sciences’ Q3 2025 earnings at $2.12 EPS, Q1 2026 earnings at $1.43 EPS and FY2026 earnings at $7.18 EPS.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The business had revenue of $7.12 billion during the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.67 EPS.

Several other research analysts have also recently commented on the company. Wells Fargo & Company lowered their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. Mizuho lowered their price objective on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Barclays reduced their target price on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a report on Monday, February 12th. Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price target for the stock from $91.00 to $82.00 in a report on Thursday, February 22nd. Finally, HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a report on Wednesday. Ten investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $84.57.

Gilead Sciences Stock Up 0.1 %

Gilead Sciences stock opened at $67.08 on Wednesday. The firm has a market capitalization of $83.52 billion, a P/E ratio of 14.91, a P/E/G ratio of 0.96 and a beta of 0.19. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences has a twelve month low of $65.90 and a twelve month high of $87.86. The stock’s fifty day simple moving average is $71.56 and its 200-day simple moving average is $76.39.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 4.59%. The ex-dividend date was Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s dividend payout ratio is currently 68.44%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.29% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Global Retirement Partners LLC raised its position in Gilead Sciences by 10.3% during the third quarter. Global Retirement Partners LLC now owns 4,753 shares of the biopharmaceutical company’s stock worth $355,000 after acquiring an additional 445 shares during the last quarter. Founders Financial Securities LLC purchased a new stake in shares of Gilead Sciences in the third quarter valued at $699,000. Newbridge Financial Services Group Inc. boosted its stake in shares of Gilead Sciences by 53.3% during the third quarter. Newbridge Financial Services Group Inc. now owns 3,254 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 1,131 shares during the last quarter. Meridian Wealth Management LLC increased its position in Gilead Sciences by 96.1% during the 3rd quarter. Meridian Wealth Management LLC now owns 23,046 shares of the biopharmaceutical company’s stock worth $1,727,000 after purchasing an additional 11,293 shares in the last quarter. Finally, Wagner Wealth Management LLC raised its stake in Gilead Sciences by 16.4% in the 3rd quarter. Wagner Wealth Management LLC now owns 5,337 shares of the biopharmaceutical company’s stock valued at $400,000 after purchasing an additional 751 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.